GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (FRA:XE9) » Definitions » YoY Rev. per Sh. Growth

Xencor (FRA:XE9) YoY Rev. per Sh. Growth : 71.25% (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Xencor YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Xencor's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 was 71.25%.

Xencor's Revenue per Share for the three months ended in Mar. 2025 was €0.41.

Xencor YoY Rev. per Sh. Growth Historical Data

The historical data trend for Xencor's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor YoY Rev. per Sh. Growth Chart

Xencor Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.91 128.30 -35.30 1.65 -38.72

Xencor Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.92 -48.79 -72.65 -10.42 71.25

Xencor YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Xencor's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(1.622-2.647)/ | 2.647 |
=-38.72 %

Xencor's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY Rev. per Sh. Growth (Q: Mar. 2025 )
=(Revenue per Share (Q: Mar. 2025 )-Revenue per Share (Q: Mar. 2024 )) / | Revenue per Share (Q: Mar. 2024 )) |
=(0.411-0.24)/ | 0.24 |
=71.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xencor YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Xencor's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Xencor Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (FRA:XE9) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
SAGE UPB IOVA KALV DNTH RGLS RLAY AMLX TBPH ABUS VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
XNCR:USA XE9:Germany
Address
465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Website
https://www.xencor.com
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Xencor Headlines

No Headlines